The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl

@article{Muller2000TheMM,
  title={The Molecular Mechanism of the Insulin-mimetic/sensitizing Activity of the Antidiabetic Sulfonylurea Drug Amaryl},
  author={Günter Müller},
  journal={Molecular Medicine},
  year={2000},
  volume={6},
  pages={907-933}
}
  • G. Müller
  • Published 2000
  • Biology, Medicine
  • Molecular Medicine
The hypoglycemic sulfonylurea drugs cause reduction of blood glucose predominantly via stimulation of insulin release from pancreatic β cells. In addition, during long-term treatment, an insulin-independent blood glucose-decreasing mechanism is assumed to operate. This may include insulin-sensitizing and insulin-mimetic activity in muscle and adipose tissue. This review summarizes our current knowledge about the putative modes of action of the sulfonylurea compound, Amaryl, in pancreatic… Expand
The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
  • C. Rosak
  • Medicine
  • Journal of diabetes and its complications
  • 2002
TLDR
The third-generation sulfonylurea glimepiride is associated with a reduced risk of hypoglycemia and less weight gain than other sulfonies, and the meglitinides and D-phenylalanine derivatives are powerful prandial insulin secretagogues. Expand
Mechanisms and characteristics of sulfonylureas and glinides.
TLDR
Sulfonylureas and glinides not only stimulated the release of insulin from pancreatic cells, but also had many extrapanular hypoglycemic effect, such as reducing the clearance rate of insulin in liver, reducing the secretion of glucagon, and enhancing the sensitivity of peripheral tissues to insulin in type 2 diabetes mellitus. Expand
Novel glimepiride derivatives with potential as double-edged swords against type II diabetes
TLDR
Analysis of conventional sulphonylureas and novel glimepiride derivatives for their activities at the primary targets and downstream steps in both β-cells and adipocytes in vitro demonstrates that the insulin-releasing and fatty acid-metabolizing activities are critically dependent on both overlapping and independent structural determinants. Expand
Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
With the growing prevalence of type 2 diabetes mellitus (T2DM) the possibility of treating it with available drugs is one of the main issues. Although glycemic control and reduction of micro- andExpand
Comparative Effects of Glimepiride, Vanadyl Sulfate and Their Combination on Hypoglycemic Parameters and Oxidative Stress
The present study was performed to evaluate the effect of glimepiride, Vanadyl Sulfate (VOSO 4) or their combination on glycemic status and oxidative stress in STZ-diabetic rats and to investigateExpand
Sulfonylureas: A New Look at Old Therapy
TLDR
The discovery and mechanisms of action of sulfonylureas, and the results of clinical trials are reviewed to provide practical information on the pros and cons of their use in clinical practice. Expand
[Future targets in the treatment of type 2 diabetes].
TLDR
New agonists of the peroxisome proliferator activator receptor gamma (PPAR gamma) as well as combined PPAR alpha/gamma agonists are developed at present, but the direct modulation of insulin signal transduction is still limited to experimental studies. Expand
Zukünftige Angriffspunkte für die Therapie des Typ-2-Diabetes
TLDR
New agonists of the peroxisome proliferator activator receptor γ (PPARγ) as well as combined PPAR α/γ agonists are developed at present, but the direct modulation of insulin signal transduction is still limited to experimental studies. Expand
A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus.
TLDR
MLR-1023 100-mg once-daily for 4 weeks was the most effective dose with significant reduction in PPG AUC following a mixed meal tolerance test (MMTT) and was safe and well-tolerated in patients with type 2 diabetes. Expand
Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects.
TLDR
Glimepiride remarkably improved insulin resistance, suggested by a significant reduction in HOMA-IR, an increase in MCR-g, and a Reduction in HbA(1c) without changing extrapancreatic beta-cell function and urine CPR. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 161 REFERENCES
Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes.
  • G. Müller, K. Geisen
  • Biology, Medicine
  • Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
  • 1996
TLDR
Glimepiride exhibits a higher potency compared to glibenclamide with respect to stimulation of glucose transport, glucose transporter isoform 4 (GLUT4) translocation and lipid and glycogen synthesis in normal and insulin-resistant adipocytes and in muscle cells, as well as of the potential underlying signalling processes examined at the molecular level. Expand
Mechanisms of the glycaemic effects of sulfonylureas.
  • F. Ashcroft
  • Medicine
  • Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
  • 1996
TLDR
This review summarizes recent advances in the understanding of the molecular mechanism of sulfonylurea action, focusing on the relationship between the sulfony lurea receptor and the K-ATP channel. Expand
In vitro effects of a sulfonylurea on insulin action in adipocytes. Potentiation of insulin-stimulated hexose transport.
TLDR
It is demonstrated that tolazamide in vitro alters postreceptor insulin action without influencing the receptor, and insulin-stimulated hexose transport as the cellular process responsible for the hypoglycemic effect of sulfonylureas in adipose tissue is suggested. Expand
The Sulfonylurea Drug, Glimepiride, Stimulates Glucose Transport, Glucose Transporter Translocation, and Dephosphorylation in Insulin-Resistant Rat Adipocytes In Vitro
TLDR
It is concluded that glimepiride activates glucose transport by stimulation of GLUT1 and GLUT4 translocation in rat adipocytes via interference at a site downstream of the putative molecular defect in the signaling cascade between the insulin receptor and the glucose transport system induced by high concentrations of glucose and insulin. Expand
Sulfonylurea potentiates insulin-induced recruitment of glucose transport carrier in rat adipocytes.
TLDR
It is concluded that potentiated of the insulin-induced stimulation of the hexose transport by sulfonylureas is mainly due to a potentiation of the diabetes-induced recruitment of the glucose carrier. Expand
Postreceptor Effects of Sulfonylurea on Skeletal Muscle Glycogen Synthase Activity in Type II Diabetic Patients
TLDR
It is indicated that gliclazide, in addition to its splanchnic effects, may enhance insulin-stimulated peripheral glucose metabolism through a potentiation of insulin action on skeletal muscle glycogen synthase by a mechanism distal to the insulin-receptor kinase. Expand
Effect of glimepiride (HOE 490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse.
TLDR
The results suggest that glimepiride has a potent extrapancreatic effect on glucose metabolism and may directly stimulate glucose transport activity through phospholipid signaling pathway, but not through insulin receptor kinase signaling pathway. Expand
Direct Effects of Sulfonylurea Agents on Glucose Transport in the BC3H-1 Myocyte
TLDR
It is shown that sulfonylureas at therapeutic concentrations directly increase glucose transport into muscle cells, providing the basis for the therapeutic effect of these agents in improving peripheral glucose disposal in insulin-resistant type II (non-insulindependent) diabetes mellitus. Expand
Insulin-like and Insulin-enhancing Effects of the Sulfonylurea Glyburide on Rat Adipose Glycogen Synthase
TLDR
It is proposed that the sulfonylurea is probably acting to increase glucose transport, thus allosterically increasing the activity of a synthase phosphatase by glucose-6-P, and the net result of this would be increased dephosphorylation and activation of glycogen synthase. Expand
Clinical profile of glimepiride.
  • E. Draeger
  • Medicine
  • Diabetes research and clinical practice
  • 1995
TLDR
Clinical trials established efficacy and safety of glimepiride in comparison to placebo and glibenclamide and showed its therapeutic value, suggesting that there may be less risk of hypoglycaemia with glimePiride. Expand
...
1
2
3
4
5
...